MedinCell S.A. Logo

MedinCell S.A.

Develops long-acting injectable therapies using proprietary technology to impact global health.

MEDCL | PA

Overview

Corporate Details

ISIN(s):
FR0004065605
LEI:
969500R79U6PXCL2FF46
Country:
France
Address:
3 RUE DES FRERES LUMIERE, 34830 JACOU
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

MedinCell S.A. is a clinical and commercial-stage pharmaceutical company specializing in the development of long-acting injectable (LAI) therapies. Leveraging its proprietary drug delivery technology, the company develops a diverse portfolio of controlled-release products across various therapeutic areas. This innovative approach is designed to enhance treatment efficacy, improve patient compliance, and reduce the overall burden of care by providing sustained therapeutic effects from a single injection. MedinCell collaborates with global pharmaceutical partners to advance its pipeline and address unmet medical needs, with a core mission to impact global health by making treatments more efficient and accessible.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-05 13:46
Earnings Release
Informations privilégiées / Autres communiqués
French 310.2 KB
2025-11-05 13:46
Earnings Release
Inside Information / Other news releases
English 215.5 KB
2025-09-22 07:30
Regulatory News Service
Informations privilégiées / Autres communiqués
French 359.5 KB
2025-09-22 07:30
Regulatory News Service
Inside Information / Other news releases
English 263.8 KB
2025-09-12 07:30
Board/Management Information
Informations privilégiées / Autres communiqués
French 189.0 KB
2025-09-12 07:30
Board/Management Information
Inside Information / Other news releases
English 178.3 KB
2025-09-10 21:41
Regulatory News Service
Informations privilégiées / Autres communiqués
French 171.5 KB
2025-09-10 21:41
Regulatory News Service
Inside Information / Other news releases
English 168.1 KB
2025-06-17 17:45
Annual / Quarterly Financial Statement
Inside Information / News release on accounts, results
English 405.2 KB
2025-06-17 17:45
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 395.7 KB
2025-06-10 18:00
Report Publication Announcement
Inside Information / Other news releases
English 185.6 KB
2025-06-10 18:00
Report Publication Announcement
Informations privilégiées / Autres communiqués
French 192.0 KB
2025-06-06 18:00
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
French 183.7 KB
2025-05-28 18:00
Report Publication Announcement
Informations privilégiées / Autres communiqués
French 183.1 KB
2025-05-28 18:00
Regulatory News Service
Inside Information / Other news releases
English 156.6 KB

Automate Your Workflow. Get a real-time feed of all MedinCell S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MedinCell S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MedinCell S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-05-02 N/A Other Sell 60,000 600,006.00 EUR

Peer Companies

AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America
AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America
ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK

Talk to a Data Expert

Have a question? We'll get back to you promptly.